Related Experiment Video

Updated: Aug 19, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

The proteasome as a novel target for the treatment of breast cancer

Julian Adams1

  • 1Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA. jadams@mpi.com

Breast Disease
|February 3, 2005
PubMed

Insights

The 26S proteasome is a new target for breast cancer treatment. Inhibiting this protein-degrading complex, like with bortezomib (PS-341), shows potent antitumor effects and is being tested in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The 26S proteasome plays a crucial role in cellular protein degradation.
  • Proteasome inhibition leads to cell-cycle arrest and apoptosis.
  • Cancer cells and tumor vasculature exhibit heightened sensitivity to proteasome inhibition.

Purpose of the Study:

  • To evaluate the potential of 26S proteasome inhibition as a therapeutic strategy for breast cancer.
  • To assess the efficacy and safety of bortezomib (PS-341) in preclinical and clinical settings for breast cancer.

Main Methods:

  • Studies involved breast cancer cell lines and murine xenograft models.
  • Preclinical investigations focused on the antitumor effects of proteasome inhibition.
  • Clinical trials are evaluating bortezomib (PS-341) in cancer patients, including those with breast cancer.

Main Results:

  • Proteasome inhibition demonstrated potent antitumor effects in preclinical breast cancer models.
  • Bortezomib (PS-341) effectively inhibits proteasome activity in patients.
  • Preliminary data suggest manageable toxicity associated with bortezomib treatment.

Conclusions:

  • The 26S proteasome is a promising therapeutic target for breast cancer.
  • Bortezomib (PS-341) shows significant potential as an anticancer agent for breast cancer.
  • Ongoing clinical trials are further investigating the efficacy of PS-341 in breast cancer patients.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...